{
    "clinical_study": {
        "@rank": "4878", 
        "arm_group": [
            {
                "arm_group_label": "Low-Dose MK-8351", 
                "arm_group_type": "Experimental", 
                "description": "Low-dose MK-8351 administered as single inhaled dose."
            }, 
            {
                "arm_group_label": "High-Dose MK-8351", 
                "arm_group_type": "Experimental", 
                "description": "High-dose MK-8351 administered as a single inhaled dose."
            }, 
            {
                "arm_group_label": "Placebo to MK-8351", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching placebo to low-dose or high-dose MK-8351 administered as a single inhaled dose."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary hypothesis of the study is single doses of MK-8351 will reduce the baseline\n      early asthmatic response (EAR) as assessed by area under the curve from 0-3 hours (AUC0-3hr)\n      of forced expiratory volume (FEV1) when compared to placebo."
        }, 
        "brief_title": "A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, placebo-controlled, 4-period study. Eligible patients will undergo a\n      single-blind phase in Period 1, followed by 3 periods during which they will receive\n      low-dose MK-8351, high-dose MK-8351, or matching placebo as a single dose in a random\n      sequence crossover study design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females of non-childbearing potential (at least 1 year post-menopausal,\n             post-hysterectomy, post-oophorectomy, or with tubal ligation);\n\n          -  Males with a female partner of childbearing potential must agree to use a medically\n             acceptable method of contraception during and up to 120 days after the last dose of\n             study medication;\n\n          -  Body Mass Index (BMI) >=17 kg/m^2 and <=33 kg/m^2\n\n          -  Non-smoker and non-user of nicotine or nicotine-containing products for at least 6\n             months prior to enrollment;\n\n          -  History of allergen-induced asthma for at least 6 months prior to enrollment;\n\n          -  Able to perform reproducible pulmonary function testing;\n\n          -  Positive methacholine challenge test prior to receiving study medication;\n\n          -  Allergic response to house dust mite allergen or standardized cat pelt or hair\n             allergen extract;\n\n          -  Ability to tolerate sputum induction and to produce adequate sputum.\n\n        Exclusion Criteria:\n\n          -  History of clinically significant disease or disorder;\n\n          -  History of malignancy;\n\n          -  History of significant multiple and/or severe allergies;\n\n          -  History of milk or lactose allergies or intolerance;\n\n          -  History of anaphylactic reaction or significant intolerability to prescription or\n             non-prescription drugs or food;\n\n          -  Positive for human immunodeficiency virus (HIV), hepatitis B surface antigen, or\n             hepatitis C antibodies;\n\n          -  History of major surgery within 3 months prior to enrollment;\n\n          -  Participation in another investigational trial within 4 weeks of screening;\n\n          -  Lactating females;\n\n          -  Inability to refrain from, or anticipates the use of, any medication including herbal\n             remedies during the trial period;\n\n          -  History of receiving anti-immunoglobulin E (IgE) or immunotherapy;\n\n          -  History of serious allergies to drug or a history of hypersensitivity to inhaled\n             salbutamol, antihistamines, or any other potential asthma/anaphylaxis rescue\n             medication;\n\n          -  History of hospitalization for asthma-related illness within 3 months of screening;\n\n          -  History of emergent care more than twice in the last 12 months for asthma-related\n             illness;\n\n          -  History of life-threatening asthma;\n\n          -  Consumes >4 glasses of alcoholic beverage per day;\n\n          -  Consumes >6 servings of coffee, tea, cola, energy drinks or other caffeinated\n             beverages per day;\n\n          -  History or or current use of illicit drugs within past 24 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926002", 
            "org_study_id": "8351-003", 
            "secondary_id": "MK-8351-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low-Dose MK-8351", 
                "description": "Single administration of low-dose MK-8351.", 
                "intervention_name": "Low-Dose MK-8351", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High-Dose MK-8351", 
                "description": "High-Dose MK-8351 administered as a single inhaled dose.", 
                "intervention_name": "High-Dose MK-8351", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to MK-8351", 
                "description": "Single-Dose Matching placebo to high-dose or low-dose MK-8351.", 
                "intervention_name": "Placebo to MK-8351", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 30, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Multicenter Randomized Clinical Trial to Study the Effects of Single Doses of MK-8351 on the Early Asthmatic Response to a Lung Allergen Challenge", 
        "overall_contact": {
            "last_name": "Toll-Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-3hr of FEV1 Percent Change From Baseline", 
                "safety_issue": "No", 
                "time_frame": "3 Hours"
            }, 
            {
                "measure": "Number of Participants Experiencing Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 14 Days"
            }, 
            {
                "measure": "Number of Participants Discontinuing Study Treatment Due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 72 Hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-24h of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 Hours Post-Dose"
            }, 
            {
                "measure": "AUC0-last of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Dose"
            }, 
            {
                "measure": "AUC0-\u221e of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Dose"
            }, 
            {
                "measure": "Maximum Plasma Concentration (Cmax) of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Dose"
            }, 
            {
                "measure": "Time to Maximum Plasma Concentration (Tmax) of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Dose"
            }, 
            {
                "measure": "Apparent Half-Life (t1/2) of MK-8351", 
                "safety_issue": "No", 
                "time_frame": "Up to 72 Hours Post-Dose"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}